RaySearch Laboratories AB (publ)
RSLBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | 0.16 | -0.55 | -0.10 |
| FCF Yield | 3.70% | 7.68% | 6.38% | -0.84% |
| EV / EBITDA | 12.68 | 8.37 | 6.92 | 12.64 |
| Quality | ||||
| ROIC | 13.77% | 6.19% | 2.34% | -3.20% |
| Gross Margin | 91.65% | 89.57% | 88.74% | 92.15% |
| Cash Conversion Ratio | 1.85 | 4.14 | 11.02 | -4.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.21% | 16.79% | 8.99% | -4.71% |
| Free Cash Flow Growth | 8.55% | 96.85% | 834.33% | -116.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | 0.46 | 1.16 | 2.32 |
| Interest Coverage | 28.99 | 11.86 | 3.72 | -8.72 |
| Efficiency | ||||
| Inventory Turnover | 9.37 | 11.44 | 6.74 | 1.68 |
| Cash Conversion Cycle | 38.46 | 31.26 | 134.12 | 66.12 |